Fuchs S, Rödel C, Brunner T, Iro H, Niedobitek G, Sauer R, Grabenbauer G G
Department of Radiation Oncology, Friedrich Alexander University of Erlangen-Nürnberg, Nuremberg, Germany.
Onkologie. 2003 Feb;26(1):12-8. doi: 10.1159/000069858.
Aim of this study was to retrospectively evaluate patterns of failure, results, and prognostic factors for patients with nasopharyngeal cancer (NPC) following radiotherapy (RT) with and without concurrent chemotherapy (RCT).
Between 1978 and 1999, a total of 101 patients with NPC were treated in our hospital, of whom 53 received external megavoltage RT alone with a median total dose of 76 Gy (1978-1988), and 48 patients had RCT (1989-1999). For RCT a combination of 5-FU and cisplatin was used together with a median total dose of 72 Gy. Patterns of relapse, survival rates and toxicity as well as prognostic factors were evaluated retrospectively.
RCT was associated with a marked reduction in distant metastases: 6/48 (13%) vs. 17/53 (32%) after RT alone. Locoregional tumor persistence was only marginally lower with RCT: 10/48 (21%) vs. 17/53 (32%) following RT. Patients with RCT demonstrated a survival advantage compared to those with RT alone (5-year overall survival (OS): 64% vs. 44%, p = 0.1). OS, disease-specific survival and locoregional control rates were 53, 57, and 78% at 5 years and 47, 51 and 78% at 10 years, respectively. OS was significantly affected by histology (p = 0.007), the patients' age (p = 0.009) and gender (p = 0.01).
This retrospective study provides further evidence that both reduction of distant metastasis and enhanced local tumor control by combined radiochemotherapy may be associated with improved survival rates in NPC compared to radiation alone. Concurrent RCT is therefore considered the preferable treatment option, however, confirmation in randomized trials is still warranted.
本研究旨在回顾性评估接受放疗(RT)联合或不联合同步化疗(RCT)的鼻咽癌(NPC)患者的失败模式、治疗结果及预后因素。
1978年至1999年间,我院共治疗了101例NPC患者,其中53例仅接受了体外兆伏放疗,中位总剂量为76 Gy(1978 - 1988年),48例患者接受了RCT(1989 - 1999年)。对于RCT,使用了5-氟尿嘧啶和顺铂联合治疗,中位总剂量为72 Gy。回顾性评估复发模式、生存率、毒性以及预后因素。
RCT与远处转移显著减少相关:RCT组为6/48(13%),单纯放疗组为17/53(32%)。RCT组局部区域肿瘤残留仅略低于单纯放疗组:RCT组为10/48(21%),单纯放疗组为17/53(32%)。与单纯放疗患者相比,接受RCT的患者显示出生存优势(5年总生存率(OS):64%对44%,p = 0.1)。5年和10年的OS、疾病特异性生存率和局部区域控制率分别为53%、57%和78%以及47%、51%和78%。OS受组织学(p = 0.007)、患者年龄(p = 0.009)和性别(p = 0.01)的显著影响。
这项回顾性研究进一步证明,与单纯放疗相比,放化疗联合治疗减少远处转移和增强局部肿瘤控制可能与NPC患者生存率提高相关。因此,同步RCT被认为是更可取的治疗选择,然而,仍需随机试验予以证实。